StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)

Equities researchers at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on RVNC. Stifel Nicolaus decreased their price target on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Monday, October 28th. Piper Sandler downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Finally, HC Wainwright lowered shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Revance Therapeutics presently has an average rating of “Hold” and an average price target of $10.29.

Revance Therapeutics Trading Down 1.7 %

Shares of RVNC stock opened at $5.80 on Friday. The stock has a market capitalization of $607.96 million, a P/E ratio of -1.82 and a beta of 0.98. The firm’s 50 day moving average is $5.78 and its 200 day moving average is $4.36. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to the consensus estimate of $66.30 million. The firm’s revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.80) EPS. As a group, equities analysts predict that Revance Therapeutics will post -1.53 earnings per share for the current year.

Hedge Funds Weigh In On Revance Therapeutics

Several hedge funds have recently modified their holdings of the stock. Certuity LLC bought a new stake in Revance Therapeutics in the 2nd quarter valued at $26,000. Creative Planning bought a new position in shares of Revance Therapeutics during the 3rd quarter valued at about $56,000. Clarity Capital Partners LLC purchased a new position in shares of Revance Therapeutics during the first quarter valued at about $59,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Revance Therapeutics in the second quarter worth about $33,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Revance Therapeutics in the second quarter worth about $38,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.